Introduction
============

Overweight and obesity have become a worldwide epidemic with growing prevalence across all age groups around the world \[[@B1]\]. The dramatic increase in the number of overweight and obese adults has been attributed in part by changes in dietary and lifestyle patterns in both developed and developing countries \[[@B2]\]. Overweight and obesity are well-documented risk factors for diabetes, hypertension, dyslipidemia, asthma, arthritis and coronary heart disease \[[@B3]\].

Several animal and cellular studies have provided evidences of soy proteins and soy products in maintaining optimal body weight \[[@B4]\]. Soy products also potentiate insulin secretion and insulin sensitivity in murine diabetic models \[[@B5]\]. Fermentation of soybean products has also been reported to increase the bioactivity of the functional elements \[[@B6]-[@B9]\].

Korea has experienced major changes in dietary habits in recent years due to increased affluence and western cultural influences. These changes have resulted in a greater variety of foods with low cost food supplies, resulting in an increase in metabolic diseases such as obesity and diabetes \[[@B10]\]. Although the increased energy consumption is responsible for much of the increases in the prevalence of obesity, changes in dietary choices favoring western-style foods with less traditional foods contribute to the risks of metabolic diseases \[[@B11]\]. The traditional Korean diet is characterized by a variety of fermented soybean and vegetable-based foods that contain several bioactive compounds promoting cardiovascular health and glucose regulation \[[@B12]\]. *Doenjang*, a fermented soybean paste, has traditionally been one of the most widely used seasonings in Korean cuisine. *Doenjang* is manufactured from *meju*, a product of cooked and crushed soybeans, fermented primarily by *Bacillus subtilis* and molds, such as *Rhizopus*, *Mucor* and *Aspergillus* \[[@B13]\]. Traditionally prepared *Doenjang* thus contains most of the nutritive and biologically active functional components found in soybeans, and are often in more biologically available forms than those in raw soybeans. For instance, *Doenjang* contains trypsin inhibitors, free isoflavones, saponins, phytic acid and linoleic acid, which are produced during fermentation \[[@B7]\]. Soybean isoflavones, in mostly their glucoside forms (genistin, daidzin, glycitin), are metabolized into aglycones (genistein, daidzein, glycitein) during fermentation. Isoflavonoids from legumes are reported to be hydrolyzed by microorganisms in the large intestine prior to absorption. It has been suggested that the aglycone forms of isoflavones are more effectively absorbed than the glycosides \[[@B7]\]. Accordingly, *Doenjang* has received attention from both the public and the industry, as many studies have reported its healthful physiological effects.

In the past decade, *Doenjang* has been documented as having anti-mutagenic \[[@B14]\], hypotensive \[[@B15]\], anticancer \[[@B16]\], anti-oxidative \[[@B17],[@B18]\] and anti-inflammatory properties \[[@B19]\]. Recently, anti-obesity effects of *Doenjang* and genistein have been observed in animals \[[@B9],[@B20]-[@B22]\]. In five published reports, genistein enhanced the transcription of carnitine palmitoyltransferase (CPT)-I, a rate regulating an enzyme for fatty acid oxidation, and also activated peroxisome proliferator-activated receptor (PPAR)-alpha target genes involved in fatty acid beta-oxidation \[[@B9],[@B20]-[@B23]\].

To date, the efficacy of *Doenjang* as an anti-obesogenic functional food has been documented in animal models; however, it has yet been evaluated inhuman studies. We aimed to test the hypothesis that *Doenjang* supplementation for 12 weeks reduces body weight and body fat composition as assessed by anthropometric measurements and CT scans in overweight adults using a randomized, double-blind, placebo-controlled design.

Subjects and Methods
====================

Subjects
--------

The subjects for this study were recruited from the Clinical Trial Center for Functional Foods (CTCF2) in Chonbuk National University Hospital in Jeonju, Korea during the period between June-August 2008. A total of 83 healthy men and women (19-60 years) agreed to participate. Only those subjects who were overweight (both genders: BMI ≥ 23 kg/m^2^; WHR ≥ 0.90 for males; WHR ≥ 0.85 for females) and who had no other diagnosed illnesses were invited to participate in the study.

Sixty subjects who met the study criteria were randomly divided either into the *Doenjang* (n = 30, dry 9.9 g/d) group or the placebo group (n = 30, dry 9.9 g/d with inactive ingredients). The exclusion criteria for the study were as follows: subjects with lipid metabolism disorders, \> 10% change in body weight in the past 3 months, cardiovascular disease (e.g., history of arrhythmia, heart failure, myocardial infarction), wearing a pacemaker, allergy or hypersensitivity to any of the ingredients in the test products, gastrointestinal diseases (e.g., Crohn\'s disease) or gastrointestinal surgery (e.g., a caecum or enterocele surgery), participation in other clinical trials within the past 2 months, abnormal hepatic liver function, renal disease such as acute/chronic renal failure, nephrotic syndrome, use of anti-psychosis drug therapy within the previous 2 months, laboratory tests, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study, history of alcohol or substance abuse, pregnancy and/or breastfeeding a child. Sixty potentially eligible subjects were invited to the screening examination and were enrolled in this study. All subjects signed written informed consent forms before participating in the study. The research protocol used in this study was approved by the Institutional Review Board (IRB) of CTCF2, Chonbuk National University Hospital in Jeonju, Korea.

Study design
------------

This study was a 12 week, randomized, double-blind, placebo controlled clinical trial that followed a screening period. Subjects who responded and met all of the selection criteria during a telephone interview made a screening visit. After the informed consent form was reviewed and signed, a physical examination, electrocardiogram and blood tests followed. Random numbers between 1 and 60 were generated by the computer to be assigned to each subject. The enrolled subjects were scheduled for the baseline visit when they were randomly assigned into either the *Doenjang* group (n = 30) or the placebo group (n = 30). The *Doenjang* group took 9.9 g/d (3.3 g pills/pack, three times/d) of freeze-dried *Doenjang* for 12 weeks, which was equivalent to 40 g of fresh *Doenjang*. The placebo group took the same amount of isocaloric placebo pills that were indistinguishable by shape, size, color and flavor, but without the active ingredients present in *Doenjang* ([Table 1](#T1){ref-type="table"}). *Doenjang* produced by the traditional method was purchased and freeze-dried using a freeze dryer (model PVTFD 100R, Ilsinlab, Yangu, Republic of Korea), and were then made into pills (Imshil Herbal Medicine Co, Imsil, Republic of Korea). The subjects were provided with *Doenjang* or placebo pills every 4 weeks. They were also instructed to maintain their usual dietary habits and activity levels, and use no other functional foods or dietary supplements during the 12-week intervention period.

Assessments
-----------

The subjects were asked to make a total number of five visits to the clinic: The initial screening, week 0, and at weeks 4, 8 and 12. At the initial screening visit, information on demographics, smoking, alcohol drinking, medical history, dietary intakes and vital signs were obtained; a urinary pregnancy test was conducted for women of child-bearing age. At week 0 and at the end of the 12-week intervention, anthropometric, biochemical parameters and computed tomography were measured for both groups. Anthropometric parameters (weight, BMI, body fat mass, % body fat, lean body mass and WHR) were measured using bioelectrical impedance analysis (Inbody 3.0, Biospace Co., Seoul, Korea). Fasting blood samples (\> 12 hr) were analyzed for the blood lipid profile: total cholesterol, triglycerides, high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), free fatty acid, apolipoprotein AI (Apo AI) and apolipoprotein B (Apo B). Blood tests were conducted with a Hitachi 7600-110 analyzer (Hitachi High-Technologies Corp., Tokyo, Japan) by the standard methods used at the clinical laboratory of Chonbuk National University Hospital. At both times, visceral fat area, subcutaneous fat area and total fat area were also measured using multi detector-row computed tomography scanning (SomatomSensation16, Siemens, Forchheim, Germany); visceral to subcutaneous ratios (VSR) were also calculated. At weeks 4 and 8 of the study, the subjects were interviewed for their current medication use, self-reported symptoms or side effects, changes in physical activities, lifestyles and eating patterns and pill compliances.

All participants completed a 3-day dietary record including two week days and one weekend day in order to evaluate the energy intake and diet quality at each clinic visit. Dietary intake data were analyzed by the same dietitian, using Can-Pro 3.0 software (The Korean Nutrition Society, Seoul, Republic of Korea).

Safety measurements
-------------------

Safety assessments at the baseline and conclusion of the study also included an electrocardiogram, a hematology test and complete blood chemistry: white blood cells, red blood cells, hemoglobin, hematocrit, platelet count, total protein, albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN) and creatinine. At each of the five visits, the pulse and blood pressure were measured after a 5minrest, using the digital blood pressure monitor (OMRONT4 Corp., Tokyo, Japan).

Statistical analysis
--------------------

The statistical analyses were performed using the SAS version 9.0 for Windows (SAS Institute, Cary, NC, USA). Data are expressed as mean and standard errors (SE).

The sample size for the study was based on the mean (standard error) cm^2^ of visceral fat difference between treatments in the previous study \[[@B25]\], -7.8 (3.6) cm^2^ for the experimental group and +3.9 (6.4) cm^2^ for the placebo group. It estimated to provide 80% power in order to detect a difference between groups in visceral fat of 11.7 (standard deviation; 20.5) cm^2^ with α = 0.05, using a 2-tailed *t*-test of the difference between the means. A sample size of forty eight participants (24 per group), determined by calculation when considering a 20% dropout rate of the total 60 participants, were selected.

Between subjects t-tests were calculated for all variables measures in order to determine whether there were changes associated with the treatment group. Within each treatment group, paired comparison t-tests were calculated to test whether there was a change from 0 week to 12 weeks, or whether the last available value was significantly different from zero. Repeated measures analysis of variance was performed in order to see whether there were effects associated with time (with-person variable), treatment group (between-group variable) or with the interaction of time and the treatment group. The estimated outcome for the absolute change at 12 weeks (95% confidence interval \[95CIs\]) were calculated for the mean absolute change in the treatment and placebo groups at 12 weeks and for a global test for the treatment effect over the entire trial period. Changes in measurements over the 12-week study period were obtained by calculating the difference between the 0 week (pre) and post-intervention measurement in each group.

Results
=======

Recruitment and study subjects
------------------------------

The sampling and trial profiles for the number of subjects initially screened and for those who completed or withdrew from the study are summarized in [Fig. 1](#F1){ref-type="fig"}. Of the 83 pre-screened subjects at the onset, 23 subjects were excluded for not meeting the selection criteria either by laboratory tests and/or physical examinations. The remaining 60 subjects were divided equally and randomly between the *Doenjang* (n = 30) and placebo (n = 30) groups.

Four participants from the *Doenjang* group (13%) and five participants from the placebo group (16%) failed to complete the study. Seven participants were disqualified because of their inadequate intake of the prescribed supplements or by not participating in other aspects of the study; two participants voluntarily withdrew. At the end, 51 subjects (*Doenjang* = 26, placebo = 25) remained in the study.

General characteristics and dietary assessment of subjects
----------------------------------------------------------

The experimental and placebo groups were similar in socio-demographic characteristics ([Table 2](#T2){ref-type="table"}). The dietary intakes of macro- and micro-nutrients did not change over time nor did they differ between the two groups over the course of the 12-week intervention (Data not shown).

Body weight and components
--------------------------

Body weight and composition data are summarized in [Table 3](#T3){ref-type="table"}. After 12 weeks of supplementation, subjects in the *Doenjang* group showed a significant reduction in body weight (*P* \< 0.001), body fat mass (*P* \< 0.001) and % body fat (*P* \< 0.01), without showing changes in the waist-hip-ratio (WHR) compared with those of the placebo group. The decreases in the mean values for body weight (kg) and body fat (%) in the *Doenjang* group over the 12 weeks were 0.8 and 0.6, respectively.

Abdominal fat distribution by computerized tomography
-----------------------------------------------------

Abdominal fat distribution data quantified by computerized tomography are presented in [Table 3](#T3){ref-type="table"}. After the 12-week intervention, the *Doenjang* group exhibited significant reduction in total fat area (-84.3 cm^2^), visceral fat area (-8.6 cm^2^) and subcutaneous fat area (-75.7 cm^2^). The placebo group also had reductions in total fat area (-74.4 cm^2^), visceral fat area (-0.9 cm^2^) and subcutaneous fat area (-73.8 cm^2^). The *Doenjang* group showed significantly reduced visceral fat area compared to the placebo group (*P* \< 0.05).

Lipid profiles
--------------

As portrayed in [Table 4](#T4){ref-type="table"}, after the 12-week intervention, the serum concentration of total cholesterol, LDL-C, Apo AI and Apo B decreased significantly in the *Doenjang* group (*P* \< 0.001). The degree of reduction in the *Doenjang* group however did not differ from those observed in the placebo group.

Safety measurements
-------------------

At each clinic visit, the investigators probed the subjects to observe if they experienced any side effects since the previous visit. No moderate or serious adverse events were reported during the 12-week study period. The evaluation was also expanded to include laboratory tests, electrocardiogram and vital signs (blood pressure, pulse) during the subjects\' visits. The results of the clinical tests were in the normal range; hence, no subjects withdrew due to adverse effects.

Discussion
==========

Many studies evaluate the effects of dietary interventions on weight loss in subjects on a low calorie diet, and therefore, assess the additive effect of the intervention in a group of subjects following a weight loss program. This study took a different approach; we evaluated the effect of adding a traditional food, *Doenjang*, to the diet of overweight subjects following a normal diet and lifestyle.

*Doenjang* is one of the most widely used fermented seasonings in Korean food culture. Anti-obesogenic effects of *Doenjang* and genistein have recently been reported in both cellular and animal studies \[[@B9],[@B20]-[@B23]\]. It is generally accepted that the beneficial effects of genistein are mainly mediated by the changes in the expression of genes involved in cholesterol metabolism, such as hydroxymethylglutaryl-CoA (HMG-CoA) reductase and LDL receptor \[[@B21]\]. Furthermore, genistein and daidzein both increasehepatic CPT-1 enzyme activity by up-regulating CPT-1 transcription, a rate regulating the enzyme of fatty acid oxidation. The increase in fatty acid oxidation results in increased energy expenditure, leading to decreased body fat and weight \[[@B9],[@B20]\]. Other research findings have shown that *Doenjang* reduces hyperlipidemia in rats fed with a high fat/high cholesterol diet \[[@B21]\]. Green tea-*Doenjang* was shown to exert anti-obesity activity in rats fed with high fat diets \[[@B22]\]. Among Korean traditional fermented soybean products, *Doenjang* shows the greatest efficacy for reducing body weight and exhibits lipid lowering activities in rats \[[@B24]\]. Animal experiments have consistently shown that *Doenjang*-containing food products are effective for weight loss \[[@B9],[@B22]-[@B24]\]. These studies have suggested that *Doenjang* has more positive effects on weight management than any other soybean products, partially due to its longer fermentation and ripening process. However, the doses used in many of the cited animal studies were higher than would ever be used for human diets. Therefore, this study was designed to evaluate its effects in humans at dietary levels that are realistic for human consumption. We thus hypothesized that *Doenjang* (Korean fermented soybean paste) supplementation will result in favorable changes in anthropometric parameters and abdominal fat distribution as assessed by CT scans and lipid profiles in overweight subjects (BMI ≥ 23 kg/m^2^).

We found that subjects in the *Doenjang* group had decreased mean body weight, body fat mass and % body fat without changing WHR when compared to the baseline data. Although the placebo group experienced decreases in two of the four above mentioned parameters, reduction in body weight (*P* \< 0.001), body fat mass (*P* \< 0.001) and % body fat (*P* \< 0.01) were significantly less than the *Doenjang* group and did reach a statistical significance. In a previous study, L-carnitine and isoflavone supplements given to overweight/obese women for 12 weeks resulted in a significant decrease in body weight and percent body fat in the treatment group, whereas in the placebo group, body weight and percent body fat remained unchanged \[[@B25]\]. Of the obese subjects, those who tended to have a higher visceral fat percentage than subcutaneous fat, and higher abdominal fat percentages than posterior fat, were at increased risk for atherosclerosis. The risk for cardiovascular diseases is common in people with abnormal metabolic activities. Previous reports have demonstrated that visceral fat accumulation is specifically associated with metabolic alterations (e.g., insulin resistance, elevated serum triglycerides) of obesity \[[@B26],[@B27]\].

In this study, CT scans showed that the abdominal fat area, i.e., total fat area and subcutaneous fat area were significantly reduced in both groups after the intervention period; however, the differences were not significant between the groups. On the other hand, the visceral fat area was significantly reduced by -8.6 cm^2^ (*P* \< 0.001) in the *Doenjang* group, whereas no change was realized in the placebo group (-0.6 cm^2^). In particular, the *Doenjang* group showed significantly reduced visceral fat area compared with the placebo group (*P* \< 0.05). Other investigators have reported that taking 75 mg/day of isoflavone for one year resulted in no improvements in BMI or body fat distribution; however, trunk fat mass significantly decreased \[[@B28]\]. Gwak et al. \[[@B25]\] found that L-carnitine and isoflavone supplements given to overweight women for 12 weeks significantly decreased both the total fat area at the L4 level and the visceral fat area, which was similar to the findings of this study. Therefore, prolonged intake of isoflavone-rich soybeans and fermented bean products, such as *Doenjang*, seemed to decrease abdominal fat, particularly visceral fat, which is important for preventing age-related chronic diseases. The dosage used in this study was equivalent to 40 g wet weight of *Doenjang* (dry weight 9.9 g), roughly equivalent to 3 bowls of *Doenjang* soup (similar to Japanese miso soup), which contains approximately 13.3 g of *Doenjang* each, thereby supplying about 20-30 mg of isoflavones (containing 8.57 mg aglycones \[[@B29]\]) per day. This level produces plasma concentrations of isoflavones ranging around 200-300 nmol/L, which is typical of many orally-ingested therapeutics \[[@B30]\].

In a previous study, cholesterol-lowering substances were isolated from *Doenjang* and were identified as aglycones: genistein, daidzein, glycitein. Since isoflavone aglycones inhibit HMG-CoA reductase, *Doenjang* may also help prevent cardiovascular diseases \[[@B31]\]. Several animal studies have shown that *Doenjang* decreases blood triglyceride and cholesterol levels \[[@B9],[@B21],[@B22],[@B24]\]. In this study, lipid profiles and apolipoprotein concentrations did not significantly differ between the *Doenjang* and placebo groups. The lack of *Doenjang* treatment effect may be explained by the fact that the study subjects were healthy subjects with no known abnormalities in serum cholesterol and triglycerides. The serum lipid and lipoprotein concentrations of all participants fell within a normal range, therefore, the results seem to be insufficient for assessing those particular effects.

In the present study, the limitations are also its strengths. Since *Doenjang*, as a whole food, was used in the study, it is not possible to ascertain which compounds were responsible for the decreased body weight and visceral adiposity or by what mechanism due to the complex composition of *Doenjang*. However, the presence of a high level of isoflavones in *Doenjang* may be the cause. The subjects were instructed to maintain their normal dietary habits and physical activities during the 12-week intervention period; however, compliance to the instruction could not be validated. Yet, this study revealed that a whole food can have beneficial effects on body composition in a free living environment. To the best of our knowledge, no other studies, to date, have reported the effects of *Doenjang* supplementation for decreasing the risk of obesity, particularly abdominal fat, in overweight people.

The results of this study showed that 40 g (dried weight, 9.9 g) of *Doenjang* supplement for 12 weeks significantly improved body weight and abdominal obesity compared with the placebo group. We thus conclude that the intake of *Doenjang*, along with a controlled diet and exercise, would be effective for reducing abdominal fat and weight management in overweight people. Additional research on the effect of prolonged intake of *Doenjang* in a larger study and longer-term study is needed.

This study was supported by grants from the Ministry for Food, Agriculture, Forestry and Fisheries (20080410496-00).

![Flow chart for the enrollment of study subjects](nrp-6-520-g001){#F1}

###### 

Composition of *Doenjang* and placebo supplements (day)
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^\*^Ingredients of *Doenjang* before fermentation

###### 

Baseline characteristics of the subjects
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^1)^Values are expressed as means ± SE.

^2)^By independent t test

^3)^Chi-square test

BMI, body mass index; WHR, waist to hip ratio; TC, total cholesterol; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; FFA, free fatty acid; Apo AI, Apolipoprotein AI; Apo B, Apolipoprotein B.

###### 

Change of body weight and composition andabdominal fat area measurements at the 0-week and 12-week of the study
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^1)^Values are expressed as means ± SE.

WHR, waist to hip ratio; VSR, Visceral to subcutaneous ratio.

^2)^Values in this column represent the difference between the mean changes scores of the Doenjang group and those of the placebo group;95% CIs are in parentheses.

^3)^*P*values derived from repeated measures analysis (per protocol) after adjusting for age, gender and BMI.

^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01, ^\*\*\*^*P* \< 0.001 : *P*-values indicate significant differences in the variables between 0 week and 12 weeks, which were evaluated by the paired t-test.

###### 

Serum lipid profiles of *Doenjang* and placebo groups at the 0-week and at the 12-week of the study

![](nrp-6-520-i004)

^1)^Values are expressed as means ± SE.

HDL-C, High-density lipoprotein cholesterol; LDL-C, Low-density lipoprotein cholesterol; Apo AI, Apolipoprotein AI; Apo B, Apolipoprotein B.

^2)^Values in this column represent the difference between the mean changes scores of the Doenjang group and those of the placebo group; 95% CIs are in parentheses.

^3)^*P* values derived from repeated measures analysis (per protocol) after adjusting for age, gender and BMI.

^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01: *P*-values indicate significant differences in the variables between 0 week and 12 weeks, which were evaluated by the paired t-test.

[^1]: ^\*^These two authors contributed equally to this study.
